We have a long history of working in partnership with others. Indeed, some of our greatest achievements have come about through collaborative effort.
The Department of Health (DH) defines joint working between the NHS and the pharmaceutical industry as situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery. Our ability to continue with our long-standing collaborative efforts pivots on the DH’s joint working mandate and enables us to discover and invent new ways, every day, to help the world be well.
We're currently working with the NHS in numerous ways, across various disciplines and disease areas. Whether it's cost reductions, improved quality of patient care or access to the latest research in a specialist area, we do what we can to help.
This is the executive summary of the joint working agreement between Merck Sharp and Dohme Limited (MSD), Astra Zeneca (AZ), University of Glasgow and NHS Greater Glasgow & Clyde (NHS GG&C). This agreement lasts from November 2015 to May 2017 (to be extended if project incomplete at this date).
Obesity and type 2 diabetes – raising the issue of weight management in primary care
This project will develop a primary care educational package in order to generate a greater number of referrals of patients with type 2 diabetes and obesity from primary care, who are ready and willing to consider weight management, to NHS weight management services. The education will consist of an online learning module covering the benefits of weight loss in diabetes, the effectiveness of weight management services, communication skills training for raising the issue, the safe management of diabetes during weight loss and details of local services and a complementary face to face training course. An implementation toolkit will be developed for use in each practice. The project will be fully evaluated with a cluster randomised trial focusing on patient outcomes. The project consists of a feasibility pilot, a full evaluation and, if successful, full rollout across NHS GG&C.
Scottish Intercollegiate Guideline Network (SIGN) guidance recommends that “obese adults with type 2 diabetes should be offered individualised interventions to encourage weight loss (including lifestyle, pharmacological or surgical interventions) in order to improve metabolic control”. In NHS GG&C there are currently 44870 patients with type 2 diabetes (data from Scottish Diabetes Surgery 2013) yet only 658 patients with type 2 diabetes were referred to Glasgow and Clyde Weight Management service in the year 2008-9. Of those, only 378 attended at least 1 session and we know that less than half of these will have lost at least 5kg. There are a numbers of barriers to appropriate treatment (medications and referral to weight management services) of patients with co-existent obesity and type 2 diabetes including patient’s lack of knowledge of the benefits of and support available for weight loss, Lack of knowledge by clinicians, lack of confidence by clinicians and negative opinions by clinicians
To ensure that patients who are overweight or obese and have type 2 diabetes are identified, receive personalised diabetes care, have the issue of weight raised and explained in a non-judgemental manner by staff in primary care, and are referred on to weight management services ensuring equity of access across NHS Greater Glasgow and Clyde.
Pilot of 10 practices (5 current high referrers, 5 current low referrers). The training would be offered as planned and resource delivered to practices. After a 2 month period a process evaluation would be conducted covering:
Pilot success will be defined by delivery of an accessible online learning platform and face to face learning. The components of the intervention may be modified in view of feedback from participants.
The project will be evaluated via a pragmatic 3 arm cluster randomised trial at the level of GP practice (sample size based on data from pilot study). This will be real life so the opportunity to use the education and tools will be given, but practices cannot be made to attend or use the materials.
The three groups will be:
Success criteria will be:
Using routine referral data which is collected electronically by NHS GG&C already. Intervention practices versus control practices:
A subgroup of practices (approx. 10) will undergo confidence mapping to assess the final version of the online learning package.
Subject to NHSGGC review it is hoped that the proposed project will be adopted into mainstay healthcare provision by weight management services and health improvement +/- some industry support of refresher training. The steering group may wish to publish a project review to share and communicate learning both within the board and across other territorial boards within NHS Scotland & other parts of the UK where appropriate.
The aim is to create a safe, effective and person centered intervention for patients with T2DM requiring weight management. Key to this will be the early identification of key issues relating to patients T2DM & weight early in the care journey and non-judgmental, caring and appropriate consultations with referral options made available to all eligible patients. A better understanding of the link between weight management and T2DM will hopefully raise patient engagement and self-management.
For the institution: The development of a package offering training and materials to improve and standardize raising the issue of weight loss in patients with diabetes. It is hoped this will lead to an increase in appropriate patient referrals by primary care and an increased uptake of services by patients to create improved pathway flow. Also anticipated is increasingly ‘personalised’ treatment of diabetes for obese patients within the parameters of the current evidence based guidelines improving quality and reducing clinical variation.
For the industry partners: Supporting NHSGGC & other NHS stakeholders so that the appropriate patients with T2DM receive the appropriate treatment at the appropriate time reflective of local & national guidelines. A secondary benefit is being able to demonstrate that MSD & AZ are trusted partners in optimising and enhancing diabetes care through deployment of resources to support and facilitate higher quality care for all appropriate patients. The ability to apply shared skill, expertise and resources to further enhance patient outcomes and service performance will prove the suitability as a partner organisation to the NHS.
This is the executive summary of the joint working agreement between Merck Sharp and Dohme Limited (MSD) and the South London Health Innovation Network. This agreement lasts from April 2015 to October 2015.
The improvement of integration care pathways for the arrangement of unscheduled care in hypoglycaemia and hyperglycaemia (South London Health Innovation Network Hypo Pathway Project).
In October 2012, LAS launched a new pathway in which GPs are informed within 24-48hrs (with patient consent) where an ambulance crew has treated a hypoglycaemic episode on scene (no hospital conveyance). LAS identified a need to evaluate implementation of this pathway and it was agreed that the Health Innovation Network would provide the capacity and expertise to support this evaluation. It was decided that, using the results of the evaluation, HIN and LAS would then work with service users and providers across the 12 South London CCGs to improve the pathway and in this way deliver enhanced patient outcomes.
The objective of the project is to maximise the benefits of the hypo/hyperglycaemic pathway and ensure that patients receive integrated and tailored care to reduce the risk of these events occurring, many of which are avoidable and increase referral rates to 100%.
Through the enhanced knowledge and confidence of LAS staff attending to patients, the recording of information in a standardised way and the subsequent follow up by designated HCPs, patients will have access to a better, more cohesive standard of care and it is anticipated will have better outcomes as a result.
HIN - This project directly helps the South London Health Innovation Network to attain their goal of delivering cross boundary working within their membership to improve health outcomes for South London residents.
LAS – This project helps LAS by working to reduce the number of avoidable hypoglycaemic episodes and by providing the reassurance that patients will receive optimal follow up care after ambulance staff have delivered treatment on scene.
NHS Southwest Long Acting Reversible Contraception (LARC) Implementation Project
NHS South West, MSD and Bayer HealthCare are working in partnership to achieve region-wide implementation of National Institute for Health and Clinical Excellence (NICE) LARC Guidance, October 2005. This collaborative project aims to impact on region-wide teenage pregnancy rates, unintended pregnancy rates and abortion rates.
Better access to the full range of contraceptive options and increased support to areas of highest need to help reduce health inequalities.
Primary Care Diabetes Facilitator Project
The parties involved are working together to increase management of diabetes in Primary Care, to reduce unplanned hospital admissions, to improve early identification of patients at high risk of developing diabetes, to ensure prescription of diabetes medicines in line with NICE recommendations, to improve compliance and frequency of medical reviews and to improve the cost effectiveness of current services within the NHS.
Better management of diabetes in Primary Care, fewer unplanned hospital admissions, early identification and subsequent advice on making a positive lifestyle choice and an overall benefit from the improvements to the cost-effectiveness of NHS services.
End of 2012
NHS Nottingham City and Industry Maximising Resources and Outcomes in Diabetes (NIMROD)
NIMROD will seek to understand why the rates for diabetes-related hospital admissions in Nottingham City are higher than national average and then take steps to reduce the number of avoidable hospital admissions for people with diabetes and diabetes-related illness.
Aside from benefits gained from increased quality and efficiency, patients are expected to benefit from a reduction in avoidable hospital admissions in Nottingham and from the programme's objective to ensure that all patients with diabetes in Nottingham City are treated in line with current best national practice i.e.NICE and local clinical guidelines.
End of 2012
This is the executive summary of the joint working agreement between Merck, Sharp and Dohme Limited (MSD) and London Sexual Health Programme (NHS England, London) and Bayer HealthCare.
Improving Choices in Contraception through Training
This partnership is designed to support NHS London in the implementation of NICE LARC Guidelines (NICE CG30, published in 2005) with peripatetic trainers delivering training and education to Healthcare Professionals in their practices in London.
Improved access to LARC, in particular, intrauterine system (“IUS”), intrauterine device (“IUD”) and subdermal implant (“SDI”).
Enable patients to make a more informed decision when choosing contraception appropriate to their lifestyle.
Reduction in unintended pregnancies in women of all age groups and termination of pregnancy (TOP) rates.
Reduced variation in Long Acting Reversible Contraception (“LARC”) uptake across NHS London by focusing on areas of low uptake and limited access to LARC.
Upskilling, training and delivery of LARC training to healthcare professionals in London to the nationally recognised standards set by the Faculty of Sexual and Reproductive Healthcare (“FSRH”) and the Royal College of Nurses (“RCN”).
Increase the number of fitters of three LARC methods equally (IUS, IUD, SDI), from both doctors and nurses across boroughs within NHS London. Fitters will also be trained on how to remove the LARC.
Reduction in unintended pregnancies in women of all age groups and termination of pregnancy (TOP) rates.
Increased uptake of each of the three LARC methods (IUS, IUD and SDI) by the implementation of the NICE Guideline on Long Acting Reversible Contraception (CG30) within general practice and sexual and reproductive health services.
Both MSD and Bayer manufacture a LARC method and therefore increasing LARC uptake will benefit all Parties of the Joint Project Group.
Actively demonstrate the added value that MSD can bring to patients and the NHS through collaborative working which utilises MSD's skills, experience and resources.
Transforming Community Services in Diabetes - Developing Skills and Competencies in Primary and Community Care
This programme has been designed to develop the skills of staff in primary and community care. It will utilise skills and expertise from within the pharmaceutical industry combined with the Care Trust Plus's knowledge of the community in Blackburn to deliver improved services on a local basis.
By up-skilling and training Healthcare Professionals (HCPs), healthcare will be improved in the Blackburn area which will ultimately reduce hospital admissions, re-admissions and referrals.
End of June 2012
Adult Diabetes Service Project
The contributors to this project are working together to redesign the provision of diabetes primary care to provide a service that is not only accessible, fair, equitable and personalised. These improvements will be implemented in the hope of reducing inequalities and making the best use of available resources.
Greater access to diabetes care in Central Lancashire, in a way that allows greater choice of care to suit individual needs and circumstances.
End of 2012
Department of Health (DoH) supported Pathfinder Project on Public and Patient Engagement (PPE). Branded locally as 'myNHS myVoice'.
This project aims to deliver a feasibility study that will enable Clinical Commissioning Groups (CCGs) to better understand their population and work with the local population to develop future services.
With the aim to recruit 5,000 people to myNHS myVoice (the Leodis Patient Panel), patients are expected to benefit from being given the choice to engage on subject in which they had a personal interest or involvement, as well as an increased awareness of the potential for future, service shaping, involvement. Patients will have greater influence on pathway redesign as well as commissioning and will help to develop a service in which they are involved in a way that suits them.
30th April 2012
Pulmonary Advancement Network for Newark and Sherwood Health (PANNASH)
This project aims to enhance primary care and treatment received at home for sufferers of Chronic Obstructive Pulmonary Disease (COPD). The project will also aim to improve the abilities of Newark and Sherwood CCG Healthcare providers.
Reduction in emergency hospital admissions and better health for people suffering from COPD
This is the executive summary of the joint working agreement between Merck, Sharp and Dohme Limited (MSD) and South East Coast Ambulance Service, Surrey Downs CCG & North West Surrey CCG.
Reducing Repeat Ambulance calls for Diabetic Hypoglycaemia – The Surrey Hypo Pathway project.
The aim of the project is to improve the care of patients living with diabetes (type 1 and type 2) by reducing avoidable episodes of severe hypoglycaemia, through increasing disease review and more effective aftercare following a hypoglycaemic event.
Improved identification, recording and reporting of non-conveyed and conveyed patients suffering hypoglycaemic episodes by the ambulance service will result in better diabetes related health outcomes.
The project involves developing robust clinical management pathways between South East Coast Ambulance Service (SECAmb) and both primary care and community diabetes providers.
Improved communication between healthcare professionals and timely patient follow up will ensure that patients at risk of further hypoglycaemic events are followed up and managed more appropriately.
A follow-up review will promote better health outcomes and reduce subsequent 999 ambulance call outs.
The project will develop the knowledge and skills of ambulance staff to improve their understanding and recognition of diabetic hypoglycaemia through face to face training and eLearning resources.
Develop and implement a defined pathway for the reporting and subsequent management of patients who have suffered an episode of hypoglycaemia which has resulted in an ambulance call out.
Improved reputation as a collaborative partner to the NHS and provider of healthcare solutions and resources.
Identification of patients at risk of hypoglycaemia who may benefit from alternative oral anti-hyperglycaemic agents including DPP-4 inhibitors as part of a diabetes management review to prevent a subsequent hypoglycaemic event.
Ability to take and share the learnings from this project to other Health Care Organisations to support the integration of diabetes pathways across all relevant stakeholder groups.